ZNRF2 and prostate adenocarcinoma: However, there was no difference in the expression of ZNRF2 in CHOL (Cholangiocarcinoma), KIRP (Kidney renal papillary cell carcinoma), PAAD (Pancreatic adenocarcinoma) and PRAD (Prostate adenocarcinoma) (p > 0.05) compared with corresponding control tissues.